StockNews.com initiated coverage on shares of ContraFect (NASDAQ:CFRX – Get Rating) in a research report released on Saturday. The firm issued a sell rating on the biotechnology company’s stock. CFRX has been the subject of a number of other reports. Maxim Group lowered shares of ContraFect from a buy rating to a hold rating in […]
